Prostate Cancer in Black Men: Why Diagnosis Comes Later

Black men in the United States are diagnosed with prostate cancer more often than any other group, and they die from it at twice the rate of White men.

Those numbers usually get explained in one of two ways. Some people decide Black men’s bodies are simply more vulnerable to the disease. Others assume it all comes down to insurance. Neither is complete, and the explanation you accept shapes what you do next.

The better-supported picture has three overlapping causes. Biology raises risk for some men. Access to care shapes when and how men are treated.

And the diagnostic system itself decides when screening starts, what happens after an abnormal result, and whether anyone follows through.

Knowing which is which can help you push for the right testing and recognize when your own care fell short.

What the Numbers Show

The American Cancer Society’s 2025 prostate cancer report found that Black men have 67% higher incidence and twice the death rate of White men. The same report found the five-year relative survival rate approaches 100% when the cancer is found at an earlier stage, but is only 38% once it has spread to distant organs. Distant-stage diagnoses have been rising in every age group.

The picture in New York is similar. The state health department reports that Black men are one and a half times more likely to be diagnosed with prostate cancer and twice as likely to die from it, and about 17,000 New Yorkers are diagnosed each year.

A higher death rate doesn’t necessarily mean a deadlier disease. It can also mean the cancer is being found later, when it is harder to treat.

For background on the disease and the legal issues around it, see our prostate cancer malpractice overview.

How Much of the Gap Is Biology?

Some of it, but less than many people assume, and the science is still unsettled.

Researchers have identified genetic variants more common in men of African ancestry that are linked to higher prostate cancer risk.

One region of the genome, 8q24, has been studied across several populations. Some tumor studies have also found differences in genetic changes by ancestry. These findings are real, but many come from small samples, and they don’t always agree.

Family history matters too. A man whose father or brother had prostate cancer faces higher risk, and that risk climbs when the relative was diagnosed young.

Race and genetic ancestry aren’t interchangeable. Race is a social category. Populations of African ancestry carry more genetic diversity than any other group, so “Black” isn’t a single genetic profile. A finding about an ancestry-linked variant doesn’t translate into a statement about every Black man.

What Happens When Care Is Equal

This is the most important evidence in the discussion. A 2019 study in JAMA Oncology pooled more than 306,000 men from three settings: a national cancer registry, five Veterans Affairs medical centers, and four national clinical trials with standardized treatment.

In the general population, Black men had a modestly higher risk of dying from prostate cancer. In the VA, the difference was not statistically significant. In the clinical trials, Black men actually had a lower risk of dying from the disease.

A separate VA study in the journal Cancer followed more than 60,000 men. It found that 10-year prostate cancer mortality was 4.4% for African American men compared with 5.1% for White men.

Together, these studies suggest that much of the national gap reflects differences in access and care rather than tumors destined to be deadlier. That is sobering, because it ties many deaths to the system. It is also hopeful, because a system can be fixed.

Where Access Breaks Down

Access means more than having insurance. It includes whether a man can get an appointment, whether a nearby hospital has prostate MRI and targeted biopsy, and whether his plan covers the follow-up he needs.

Studies have found Black men less likely, in some data sets, to receive timely follow-up after an abnormal PSA and to be offered surgery or advanced therapies.

Trust has a history too. Documented abuses, including the Tuskegee study, left lasting caution toward the medical system. That caution can mean later visits and fewer screenings. It also means less participation in clinical trials, which leaves Black men underrepresented in the research that guides their care.

Active surveillance shows how this plays out. Because Black men were underrepresented in early surveillance studies, doctors debated whether monitoring a low-risk cancer was safe for them. More recent evidence, including VA data, supports surveillance for carefully selected Black men with low-risk disease, with close monitoring. Individual judgment matters more than a blanket rule either way.

In New York, these gaps vary by neighborhood, from the five boroughs to Buffalo, Rochester, Syracuse, and Albany.

How the Diagnostic Pathway Can Fail

Most of the standard PSA reference ranges were developed in largely White populations. Researchers are studying whether race-specific or age-specific thresholds, or measures like PSA density, work better for Black men. It’s an evolving and sometimes contested area, and a fair question to raise with your doctor.

After an abnormal PSA, the next steps matter just as much. Prostate MRI before biopsy helps find the cancers that matter, but access to it is uneven. Some risk calculators were built on mostly White patient groups, and medicine is still reexamining race-based clinical algorithms.

The most common failure is also the simplest: an abnormal result that never leads anywhere. That might be a referral that never happens, a recheck that never gets scheduled, or a result that never reaches the patient.

Our article on missed urology referrals after an abnormal PSA covers that pattern. Our page on how prostate cancer is diagnosed explains the full workup.

What New York Insurance Covers

Cost can quietly decide whether a man gets screened. The Task Force’s C grade means PSA screening falls outside the federal rule requiring no-cost coverage. New York filled part of that gap. Chapter 335 of the Laws of 2018 provides that coverage for prostate cancer screening is not subject to deductibles or coinsurance for:

• Men with a prior history of prostate cancer

• Men 40 and older with a family history

• Men 50 and older without symptoms

There are limits. State insurance law doesn’t reach every plan, and many large employers’ self-funded plans follow federal rules instead. Follow-up MRI and biopsy are separate services and can carry their own costs. Before testing, ask your insurer whether your plan is subject to New York law and how follow-up imaging is billed.

Talk With a New York Cancer Lawyer

If you or someone you love was diagnosed late and you suspect an abnormal result was missed or screening was never offered, it is worth finding out whether the delay was avoidable. Porter Law Group represents patients and families across New York, with offices in Albany, Buffalo, New York City, Rochester, and Syracuse.

Our New York cancer lawyers work with urology and oncology experts to review the full record, and you can see our results in delayed cancer diagnosis cases.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation.

Attorney advertising. This article provides general information and is not legal or medical advice. Prior results do not guarantee a similar outcome. Filing deadlines depend on the facts of each case.

Frequently Asked Questions

Why is prostate cancer more deadly in Black men?

Black men die from prostate cancer at twice the rate of White men. Some ancestry-linked genetic variants raise risk, but studies of equal-access settings such as the VA and clinical trials found the survival gap shrinks or disappears with equal treatment. That points to later diagnosis and unequal access as major drivers of the difference in deaths.

At what age should Black men start PSA screening?

The American Cancer Society recommends that Black men talk with a doctor about PSA testing at age 45, five years earlier than average-risk men. Men with more than one close relative diagnosed before 65 should start at 40. The U.S. Preventive Services Task Force has no race-specific recommendation, so the advice you get may depend on your doctor.

Is prostate cancer screening free in New York?

For many plans, it has no deductible or coinsurance. Chapter 335 of the Laws of 2018 removed those costs for men with a prior history, men 40 and older with a family history, and men 50 and older without symptoms. Self-funded employer plans may not be covered by state law, and follow-up MRI or biopsy can cost extra.

Do Black men survive prostate cancer as well as White men with equal care?

In several large studies, yes. A Veterans Affairs study of more than 60,000 men found 10-year prostate cancer mortality of 4.4% for African American men compared with 5.1% for White men. A 2019 JAMA Oncology analysis found Black men in standardized clinical trials had a lower risk of dying from the disease.

Can I sue if my prostate cancer was diagnosed late in New York?

Possibly. You would need to show that a provider departed from accepted care, such as ignoring a rising PSA or never offering testing when your risk called for it, and that the delay worsened your outcome. Under CPLR 214-a, these claims generally must be filed within two and a half years of discovery, with a seven-year outer limit.